secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2021-12-06T23:59:59+00:00
Accession:  0001564590-21-059379
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports interim Phase 1/2 BDC-1001 data: safe, 1 durable PR at 52 weeks, no CRS
--------------------------------------------------------------------------------

- BDC-1001 showed favorable safety in 57 patients; no dose-limiting toxicities up to 20 mg/kg Q3W and 12 mg/kg Q2W.
- One durable partial response maintained through 52 weeks; multiple patients with stable disease >12 weeks in 40 evaluable subjects.
- No cytokine release syndrome (CRS) observed; maximum tolerated dose not yet reached.
- Plasma/tissue biomarkers confirm TLR7/8 activation and myeloid cell infiltration consistent with mechanism of action.
- Company plans to continue monotherapy dose escalation, evaluate weekly dosing, and initiate combination with nivolumab by year-end 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021059379/0001564590-21-059379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021059379/bolt-8k_20211206.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-059379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer